Mifegyne (Mifepristone)

Mifepristone works by competitively binding to progesterone receptors, blocking the hormone’s action. This leads to breakdown of the uterine lining, detachment of the embryo, and increased uterine sensitivity to prostaglandins, facilitating termination of early pregnancy or labor induction.

The dosage of Mifegyne is determined by the prescribing clinician based on the indication, gestational age, and patient factors. Only a qualified health professional may set the appropriate regimen.

Mifegyne is used to end an early pregnancy and is therefore contraindicated in ongoing pregnancies beyond the approved gestational window. Its safety during breastfeeding has not been established, and use while nursing should be avoided unless specifically directed by a physician.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Mifegyne (mifepristone) is a progesterone receptor antagonist, whereas other abortifacients such as misoprostol act as prostaglandin analogues. Mifepristone is typically used first to prime the uterus, followed by misoprostol to complete the process, offering a two‑step regimen with high efficacy.

Mifegyne tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in extreme heat or humidity to maintain product stability.

Mifegyne is taken orally as a single tablet under medical supervision. The tablet is swallowed with water, and the patient is usually monitored for a short period before any additional medication, such as misoprostol, is given according to the treatment protocol.

Serious risks include severe infection, heavy or prolonged vaginal bleeding that may require medical intervention, and liver dysfunction. Patients should be instructed to seek immediate medical attention if they experience fever, intense abdominal pain, excessive bleeding, or signs of jaundice.

Mifegyne should not be used in women with chronic adrenal failure, severe anemia, ongoing anticoagulant therapy, known hypersensitivity to mifepristone, or when the pregnancy exceeds 10 weeks gestation. Contraindications must be evaluated by a qualified health professional before prescribing.